Oncolytic herpes simplex virus (oHSV) vectors have shown promise in the treatment of patients with recurrent brain tumors although few complete responses have accrued. Impediments to effective therapy include limited vector distribution on delivery, a consequence of injected virion particle trapping in the tumor extracellular matrix (ECM). To enhance virus delivery and spread, we investigated the use of the matrix metalloproteinase-9 (MMP-9) as a means to degrade collagen type IV, a major component of the ECM and basement membranes of gliomas that is absent in normal brain tissue. SK-N-AS neuroblastoma cells were transduced for constitutive, elevated expression of MMP-9, which did not enhance tumor cell migration in vitro or tumor progression in a murine xenograft brain tumor model. MMP-9 expression improved the distribution and infection of oHSV vectors in spheroid model in vitro. Furthermore, MMP9 induced a vector infection over larger areas of brain tumors in vivo. These results suggest that vector delivery and distribution in vivo can be improved by compromising the ECM, potentially enhancing oncolytic efficacy.
Introduction
Early phase human clinical trials have shown that oncolytic herpes simplex virus (oHSV) vectors as a therapy for recurrent brain tumors are safe without treatment-related severe adverse events and with some evidence of efficacy. 1 However, impediments remain for efficient tumor killing that relate, in part, to initial vector distribution and subsequent virus replication and spread within the tumor. In particular, the tumor extracellular matrix (ECM), which is largely produced by the tumor cells, can trap injected virus particles and prevent their diffusion. 2 Several reports describe improved oHSV vector spread and tumor mass reduction in flank tumor models of sarcomas and melanomas following coinjection with matrix metalloproteinases (MMPs). 2, 3 However, experiments evaluating the use of MMPs to enhance vector distribution in models of brain tumor, the principal intended targets of oHSV, have not been reported.
Gliomas produce an ECM rich in type IV collagen and vitronectin. MMP-9 specifically targets type IV collagen and is therefore an attractive candidate for modifying the ECM to potentially increase oncolytic virus mobility and thereby infection range. To evaluate the effect of MMP-9 expression on vector distribution, we used a new oHSV vector designated JD0G in which enhanced green fluorescent protein (eGFP) replaced ICP0 expression and the joint elements separating the unique long and short components of the viral genome were deleted. Here we show that ectopic MMP-9 expression in neuroblastoma cells (1) does not increase tumor cell migration in vitro or enhance tumor growth in the brain, and (2) increases the efficiency of infection by JD0G of tumor spheroids in vitro and promotes JD0G vector distribution throughout the intracranial tumor mass.
Results

MMP-9 expression varies in brain tumor cell lines
A matching pair of high-and low-MMP-9-expressing brain tumor cell lines was used to examine the effects of MMP-9 activity on oHSV distribution after initial vector inoculation. Western blot analysis of cell lysates of several glioma and neuroblastoma cell lines found previously to support lytic replication of HSV identified SK-N-AS neuroblastoma and U373 glioma cells as low-MMP-9 expressers (Figure 1a ). Both cell lines were stably transfected with an MMP-9 expression plasmid. MMP-9 overexpression in the transfected pools compared with the parent lines was most pronounced in SK-N-AS cells and these were used for further study (Figure 1b) .
SK-N-AS/MMP-9 cells produce increased gelatinase activity, but proliferation and HSV permissiveness are unchanged
As a measure of functional activity, MMP-9 gelatinase activity was compared between SK-N-AS/MMP-9 and parental cells. Gelatin zymography showed greater gelatinase activity in media from the transfected cells than the control cells (Figure 1c ). No significant difference in proliferation rate was observed between the MMP-9-transfected pools and the control cells over a period of 3 days (Figure 1d ). To determine whether increased MMP-9 expression affected HSV infection and/or replication, we infected SK-N-AS/MMP-9 and SK-N-AS cells with serial dilutions of a recently described oncolytic vector, JD0G (Reinhart et al., submitted). Plaque titers and morphology were similar on MMP-9 and control cells (not shown), indicating that increased MMP-9 expression did not alter virus entry or replication.
MMP-9 expression reduces the invasive capacity of SK-N-AS cells in vitro
Extracellular matrix components are involved in intercellular communications that contribute to cell migration during embryonic development, tissue repair in adult animals 4 and tumor cell infiltration. 5 Because MMP-9 is known to degrade type IV collagen, a major component of the tumor ECM, we compared the migration of SK-N-AS/MMP-9 and parental cells in Matrigel-coated transwell chambers. Remarkably, SK-N-AS/MMP-9 cells showed a reduced ability to migrate to the lower chamber compared with untransfected SK-N-AS cells (Figure 2a 
MMP-9 expression did not increase the rate of tumor progression
The contribution of MMPs to tumor growth and progression is incompletely understood, but evidence suggests that MMPs can both prevent cancer progression and encourage invasion and metastasis. 6 Accordingly, we examined the growth of SK-N-AS/MMP-9 and control tumors in nude mouse brains and determined whether MMP-9 contributed to the timing of tumorinduced lethality. The two cell lines behaved very similarly in survival experiments (Figure 3 ; P ¼ 0.12) 
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and no differences in post-mortem tumor sizes or distribution were observed (not shown).
MMP-9 enhances vector distribution following tumor injection in vivo
The finding that MMP-9 expression resulted in increased infection of tumor spheroids prompted studies to 
Discussion
This study was designed to test the hypothesis that MMP-9 modification of the ECM produced by brain tumor cells will enhance oHSV distribution and spread. SK-N-AS has low MMP-9 activity and high susceptibility to HSV infection. We created SK-N-AS cells that constitutively express exogenous MMP-9 and found that these cells had a reduced ability to migrate in vitro. Our findings are consistent with the observation that increased MMP-9 activity in vivo is associated with decreased tumor growth rate 7 and that a substantial downregulation of MMP-9 is accompanied by a threefold increase in intravasation and metastasis. 8 Moreover, MMP-9 antagonists at best provided no survival benefit to glioma patients. 9 In contrast to these findings, it has been reported that stable transfection of the human glioblastoma cell line SNB19 with a plasmid containing antisense MMP-9 cDNA decreased the invasive properties of these cells, both in vitro and in vivo. 10, 11 This discrepancy may relate to the use 
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of different cell lines, indicating a need for direct comparisons of multiple lines to distinguish general and cell-specific effects. We will address this issue in future studies using oHSV vectors engineered to express MMP-9.
Our study results comparing virus infection of both tumor spheres in vitro and brain tumors in animals showed that SK-N-AS/MMP-9 cells were more susceptible to virus infection than the control SK-N-AS cells and that the infection was more widespread. MMP-9 did not affect either infection of freshly plated cells in monolayer or tumor growth. Previous studies using Mu89 melanoma cells in a mouse skin window model showed that the treatment of tumor tissue with collagenase in combination with the oncolytic vector MGH2 resulted in enhanced vector distribution and destruction of the tumor mass without an increase in tumor spread. 2 Similarly, others have observed enhanced HSV vector distribution and tumor killing using soft tissue sarcomaderived HSTS26T cells and MMP-1 and MMP-8 to digest fibrillar collagen. 3 In another study, adenovector distribution was also enhanced by MMP-8 digestion. 12 Thus, the principle of increasing virus spread by degradation of the ECM appears to be effective for diverse OVs and across tumor types.
Although our findings indicate that modification of the ECM will facilitate homogenous vector distribution within a brain tumor mass, the exact nature of the ECM has not yet been defined for all brain tumors. Gliomas contain different collagens 13 and express multiple MMPs, including MMP-1 and MMP-3.
10,14,15 MMP-3 degrades proteoglycans, laminin, fibronectin and nonfibrillar collagen types, whereas MMP-1 degrades fibrillar collagen. In addition, these tumors express vitronectin that can be degraded by MMP-14, ADAMTS-4 and ADAMTS-5. 16, 17 Future experiments will explore the ability of MMP-9 and other MMPs to enhance oHSV vector spread and glioma tumor killing when provided as soluble proteins during vector inoculation or expressed from the vector.
Materials and methods
Cell lines and virus
Human glioblastoma SNB19, U251 and U373 (kindly provided by Dr H Okada, University of Pittsburgh), neuroblastoma SK-N-AS (ATCC, Manassas, VA, USA) and osteosarcoma U2OS (ATCC) cell lines were cultured by standard methods. To create JD0G, we deleted the internal repeat sequences ('joint') from the strain KOS HSV-1 genome, a modification that removes one copy of the gamma 34.5 gene and the immediate-early genes encoding ICP0 and ICP4. Removal of the joint enhances vector stability by eliminating internal genome rearrangements that occur during U L /U S isomerization. 18 The joint deletion removes a region spanning positions 116 982-132 605 of the HSV genome (nucleotide positions based on NC_001806). The remaining copy of ICP0 was then deleted and an eGFP expression construct driven by the human cytomegalovirus major immediate-early promoter was inserted in its place. The structure of the mutant virus was confirmed using PCR, sequencing and Southern blot analysis. JD0G virus stocks were prepared and titered on U2OS cells.
Plasmid construction and transfection
A human MMP-9 cDNA clone in pCMV6-XL4 was purchased from OriGene Technologies (Rockville, MD, USA) and cloned into pIRES1neo (Clontech Laboratories, Palo Alto, CA, USA). Stably transfected SK-N-AS/MMP-9 cells were obtained by selection with G418 (Invitrogen Corp, Carlsbad, CA, USA).
Western blotting
Cells were lysed in 1% NP40 buffer, lysates were electrophoresed through 10% SDS-polyacrylamide gels and protein blots were reacted with polyclonal anti-MMP-9 antibody (1:1000 dilution; Abcam, Cambridge, MA, USA) and HRP-conjugated anti-rabbit secondary antibody (Sigma, St Louis, MO, USA). Blots were developed with chemiluminescence substrate (Amersham 
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Pharmacia, Piscataway, NJ, USA). The lower portion of each blot was reacted with polyclonal anti-b-actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) to detect loading differences.
Gelatin zymography
Conditioned media were separated on a 10% SDSpolyacrylamide gel containing 1 mg ml À1 gelatin. The gel was washed in 10 mM Tris (pH 7.5), 2.5% Triton X-100, incubated at 37 1C for 16 h in 50 mM Tris (pH 7.5), 5 mM CaCl 2 , 1 mM ZnCl 2 , stained with Coomassie brilliant blue R-250 and destained.
Invasion assays
A total of 5 Â 10 4 cells per well were plated in Matrigelcoated or uncoated Biocoat Invasion Chambers (BD Biosciences, San Jose, CA, USA). At 22 h, cells attached to the lower surface of the membrane were stained and counted.
Spheroid culture and imaging
Spheroids were grown to approximately 1 mm in diameter in 0.5% soft agar and individually infected in microfuge tubes with 5 Â 10 4 PFU of JD0G virus for 2 h. At 24 h.p.i., the spheroids were fixed in 4% paraformaldehyde and 3 m Z section images of GFP expression were obtained by two-photon microscopy (Leica Microsystems Inc., Bannockburn, IL, USA). MetaMorph software (Molecular Devices, Downingtown, PA, USA) was used for 3D image reconstitution analysis. Separately, infected spheroids were trypsinized and GFP-expressing cells were counted under a fluorescence microscope.
Animals and tumor model
Female BALB/c nude mice (4-to 5-week old; Charles River Laboratories, Wilmington, MA, USA) were anesthetized and stereotactically injected with 5 Â 10 5 SK-N-AS/MMP-9 or control cells into the right frontal lobe as described. 19 Animals were observed daily until death or stereotactically injected at the same coordinates with viral vector (500 PFU per 2 ml of JD0G) after 3 weeks. Animals were killed 2 days later for analysis of the distribution of virus-infected cells in the tumor mass (IACUC protocol no. 07-11-383).
Histology and immunostaining
Brain tissues were fixed in 4% paraformaldehyde for 24 h and incubated in 30% sucrose for 48 h. Tissues were frozen in 2-methylbutane/dry ice, embedded in OCT, sectioned at 6 mm thickness and imaged for GFP expression under an Olympus Provis fluorescence microscope (Olympus, Center Valley, PA, USA). Alternate sections were stained with Hoechst to visualize tumor boundaries. Selected GFP-imaged sections were stained with anti-HSV antibodies (GeneTex, Irvine, CA, USA) and Cy3-conjugated sheep anti-rabbit IgG (Sigma).
